PP1
Based on 13 publication(s) in Google Scholar
PP1 is a potent, and Src family-selective tyrosine kinase inhibitor with IC50 of 5 and 6 nM for Lck and Fyn, respectively.
For research use only. We do not sell to patients.
- Purity: 99.57%
- CAS No.: 172889-26-8
- Formula: C16H19N5
- Molecular Weight:281.36
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Anti-Cancer Compound Library
HY-L025
-
Reprogramming Compound Library
HY-L039
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) PP1
More- Nat Microbiol. 2025 Nov;10(11):2949-2965. [Abstract]
- Nat Commun. 2022 Sep 27;13(1):5675. [Abstract]
- Cell Rep Med. 2025 Jan 16:101922. [Abstract]
- Cell Rep Med. 2024 May 29:101592. [Abstract]
- Front Immunol. 2021 Nov 24;12:786602. [Abstract]
- J Thromb Haemost. 2021 Aug;19(8):2029-2043. [Abstract]
- J Cell Mol Med. 2019 Apr;23(4):2399-2409. [Abstract]
- Cell Signal. 2026 Feb:138:112204. [Abstract]
- BMC Cancer. 2022 Nov 24;22(1):1211. [Abstract]
- Mol Reprod Dev. 2022 May;89(5-6):256-268. [Abstract]
- Reprod Toxicol. 2025 Mar 24:108899. [Abstract]
- bioRxiv. 2025 Jul 7:2025.07.04.663030. [Abstract]
- Patent. US20180263995A1.
Customer Validation & Images
-
WB
Biological Activity
IC50: 5 nM (Lck), 6 nM (Fyn), 250 nM (EGFR), >50 μM (JAK2)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.01 μM
Compound: PP1
|
Growth inhibition of human A549 cells
Growth inhibition of human A549 cells
|
[PMID: 28814374] |
| DOHH-2 | GI50 |
3.7 μM
Compound: PP1
|
Growth inhibition of human DOHH-2 cells measured after 72 hrs by cell titer glo luminescent cell viability assay
Growth inhibition of human DOHH-2 cells measured after 72 hrs by cell titer glo luminescent cell viability assay
|
[PMID: 37163946] |
| Jurkat | IC50 |
0.4 μM
Compound: 1
|
Inhibition of MLR stimulated IL-2 production in Jurkat cells
Inhibition of MLR stimulated IL-2 production in Jurkat cells
|
[PMID: 11012021] |
| Jurkat | IC50 |
1.2 μM
Compound: 1
|
Inhibition of anti-CD3 stimulated IL-2 production by Jurkat cells
Inhibition of anti-CD3 stimulated IL-2 production by Jurkat cells
|
[PMID: 11012021] |
| Jurkat | IC50 |
5 nM
Compound: PP1
|
Inhibition of p56 Lck tyrosine kinase in Jurkat cells where p56lck autophosphorylation is inhibited.
Inhibition of p56 Lck tyrosine kinase in Jurkat cells where p56lck autophosphorylation is inhibited.
|
10.1016/S0960-894X(97)00034-6 |
| MCF7 | EC50 |
6.76 μM
Compound: PP1
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 5 days by PrestoBlue assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 5 days by PrestoBlue assay
|
[PMID: 27115835] |
| SUD4 | GI50 |
>10 μM
Compound: PP1
|
Growth inhibition of human SU-DHL-4 cells measured after 72 hrs by cell titer glo luminescent cell viability assay
Growth inhibition of human SU-DHL-4 cells measured after 72 hrs by cell titer glo luminescent cell viability assay
|
[PMID: 37163946] |
| SU-DHL-6 | GI50 |
4.7 μM
Compound: PP1
|
Growth inhibition of human SU-DHL-6 cells measured after 72 hrs by cell titer glo luminescent cell viability assay
Growth inhibition of human SU-DHL-6 cells measured after 72 hrs by cell titer glo luminescent cell viability assay
|
[PMID: 37163946] |
PP1 inhibits Lck (IC50=5 nM) and FynT (IC50=6 nM) in vitro at concentrations significantly lower than those required to inhibit ZAP-70 (IC50>100 μM), JAK2 (IC50>50 μM), the EGFR kinase, and protein kinase A. PP1 inhibits whole cell tyrosine phosphorylation and proliferation in T cells stimulated with anti-CD3 and mitogens. PP1 selectively inhibits IL-2 gene expression over GM-CSF and IL-2R gene induction in human T cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 172889-26-8
-
Appearance Solid
-
Molecular Weight 281.36
-
Formula C16H19N5
-
Color White to off-white
-
SMILES
NC1=C2C(N(C(C)(C)C)N=C2C3=CC=C(C)C=C3)=NC=N1
-
Synonyms
AGL 1872; EI 275
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Nat Microbiol
Mycobacterium tuberculosis-derived linoleic acid increases regulatory T cell function to promote bacterial survival within macrophages. [Abstract]2025 Nov;10(11):2949-2965. PMID: 41073667 -
Nat Commun
Phosphorylation of Jhd2 by the Ras-cAMP-PKA(Tpk2) pathway regulates histone modifications and autophagy. [Abstract]2022 Sep 27;13(1):5675. PMID: 36167807 -
Cell Rep Med
MFGE8 induces anti-PD-1 therapy resistance by promoting extracellular vesicle sorting of PD-L1. [Abstract]2025 Jan 16:101922. PMID: 39842432 -
Cell Rep Med
A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. [Abstract]2024 May 29:101592. PMID: 38843841 -
Front Immunol
Fpr2/CXCL1/2 Controls Rapid Neutrophil Infiltration to Inhibit Streptococcus agalactiae Infection. [Abstract]2021 Nov 24;12:786602. PMID: 34899755 -
J Thromb Haemost
Photobiomodulation therapy for thrombocytopenia by upregulating thrombopoietin expression via the ROS-dependent Src/ERK/STAT3 signaling pathway. [Abstract]2021 Aug;19(8):2029-2043. PMID: 33501731 -
J Cell Mol Med
Knockdown of Golgi phosphoprotein 73 blocks the trafficking of matrix metalloproteinase-2 in hepatocellular carcinoma cells and inhibits cell invasion. [Abstract]2019 Apr;23(4):2399-2409. PMID: 30677226
PP1 purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Apr;23(4):2399-2409. [Abstract]
Immunoblot analysis of p-JNK1/2 (T183/Y185) in HepG2 cells treated with saracatinib (10 μM, 12 h) and PP1 (10 μM, 2 h).
-
Cell Signal
Phosphoproteomic analysis of successive Jurkat CD19-CAR generations reveals TCRζ-driven signalling. [Abstract]2026 Feb:138:112204. PMID: 41177417 -
BMC Cancer
Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors. [Abstract]2022 Nov 24;22(1):1211. PMID: 36434556 -
Mol Reprod Dev
CD55 is upregulated by cAMP/PKA/AKT and modulates human decidualization via Src and ERK pathway and decidualization-related genes. [Abstract]2022 May;89(5-6):256-268. PMID: 35474595 -
Reprod Toxicol
2025 Mar 24:108899. PMID: 40139512 -
bioRxiv
2025 Jul 7:2025.07.04.663030. PMID: 40672291 -
Solvent & Solubility
DMSO : 28 mg/mL (99.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (5.94 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.67 mg/mL (5.94 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Protein A-Sepharose beads (prepared as a 50% (w/v) suspension) are added to the antibody/lysate mixture at 250 μL/mL and allowed to incubate for 30 min at 4°C. The beads are then washed twice in 1 mL of lysis buffer and twice in 1 mL of kinase buffer (25 mM HEPES, 3 mM MnCl2, 5 mM MgCl2, and 100 μM sodium orthovanadate) and resuspended to 50% (w/v) in kinase buffer. Twenty-five microliters of the bead suspension is added to each well of the enolase-coated 96-well high protein binding plate together with an appropriate concentration of compound and [γ-32P]ATP (25 μL/well of a 200 μCi/mL solution in kinase buffer). After incubation for 20 min at 20°C, 60 μL of boiling 2× solubilization buffer containing 10 mM ATP is added to the assay wells to terminate the reactions. Thirty microliters of the samples is removed from the wells, boiled for 5 min, and run on a 7.5% SDS-polyacrylamide gel. The gels are subsequently dried and exposed to Kodak X-AR film. For quantitation, films are scanned using a Molecular Dynamics laser scanner, and the optical density of the major substrate band, enolase p46, is determined. Concentrations of compound that causes 50% inhibition of enolase phosphorylation (IC50) are determined from a plot of the density versus concentration of compound. In companion experiments for measuring the activity of compounds against Lck, the assay plate is washed with two wash cycles on a Skatron harvester using 50 mM EDTA, 1 mM ATP. Scintillation fluid (100 μL) is then added to the wells, and P incorporation is measured using a Pharmacia Biotech micro-β-counter. Concentrations of compound that causes 50% inhibition of enzyme activity (IC50) are determined from a plot of the percent inhibition of enzyme activity versus concentration of compound[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Inhibition of anti-CD3-stimulated tyrosine phosphorylation in purified human peripheral blood T cells is measured as follows. All incubations are carried out at 37°C in an Eppendorf Thermomixer 5436 at a mixing setting of 11. Cells (1×106 in 100 μL of RPMI 1640 medium) are incubated for 15 min with drug prior to a 6-min incubation with 1 μg of anti-CD3/mL (anti-leu4, 100 μg/mL). The final volume of the reaction is 115 μL. Reactions are terminated by the addition of 57.5 μL of 3× solubilization buffer incubated at 100°C prior to its addition. Samples are mixed, boiled for 5 min, and stored at -70°C. Western blots of these cell lysates, run on 10% SDS-polyacrylamide gels, are probed with a polyclonal anti-phosphotyrosine antibody, and immune complexes are detected with I-labeled protein A (ICN). For quantitation, films are scanned using a Molecular Dynamics laser scanner, and the optical densities of the major substrate band, p70, are quantitated in the presence of anti-CD3 (in the presence and absence of drug). Percent inhibition is calculated as follows: (1-(p70 optical density units in presence of drug/p70 units in absence of drug))×100. IC50 equals the concentration of compound at which 50% inhibition is measured[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Portuguese - PT (479 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5542 mL | 17.7708 mL | 35.5417 mL | 88.8541 mL |
| 5 mM | 0.7108 mL | 3.5542 mL | 7.1083 mL | 17.7708 mL | |
| 10 mM | 0.3554 mL | 1.7771 mL | 3.5542 mL | 8.8854 mL | |
| 15 mM | 0.2369 mL | 1.1847 mL | 2.3694 mL | 5.9236 mL | |
| 20 mM | 0.1777 mL | 0.8885 mL | 1.7771 mL | 4.4427 mL | |
| 25 mM | 0.1422 mL | 0.7108 mL | 1.4217 mL | 3.5542 mL | |
| 30 mM | 0.1185 mL | 0.5924 mL | 1.1847 mL | 2.9618 mL | |
| 40 mM | 0.0889 mL | 0.4443 mL | 0.8885 mL | 2.2214 mL | |
| 50 mM | 0.0711 mL | 0.3554 mL | 0.7108 mL | 1.7771 mL | |
| 60 mM | 0.0592 mL | 0.2962 mL | 0.5924 mL | 1.4809 mL | |
| 80 mM | 0.0444 mL | 0.2221 mL | 0.4443 mL | 1.1107 mL |
Powered by Bioz